Literature DB >> 10508727

Antibiotic use in humans and bacterial resistance.

D Guillemot1.   

Abstract

As with any public health problem, the evolution of antibacterial resistance must be viewed from a perspective of risk, and analysed in terms of probabilities within the populations. It is necessary to be able to predict the risk of antibacterial resistance, in the future, and two main strategies have recently been developed in mathematical models that may help to evaluate these risks. It is also important to understand how antibiotics are used and how their use affects the evolution of antibacterial resistance. Understanding the epidemiology of antibacterial resistance will enable us to develop preventive strategies to limit existing resistance and to avoid the emergence of new strains of resistant bacteria.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508727     DOI: 10.1016/s1369-5274(99)00006-5

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  23 in total

1.  Long-term shifts in patterns of antibiotic resistance in enteric bacteria.

Authors:  T Houndt; H Ochman
Journal:  Appl Environ Microbiol       Date:  2000-12       Impact factor: 4.792

2.  Bacterial cell wall compounds as promising targets of antimicrobial agents I. Antimicrobial peptides and lipopolyamines.

Authors:  Guillermo Martínez de Tejada; Susana Sánchez-Gómez; Iosu Rázquin-Olazaran; Ina Kowalski; Yani Kaconis; Lena Heinbockel; Jörg Andrä; Tobias Schürholz; Mathias Hornef; Aline Dupont; Patrick Garidel; Karl Lohner; Thomas Gutsmann; Sunil A David; Klaus Brandenburg
Journal:  Curr Drug Targets       Date:  2012-08       Impact factor: 3.465

3.  Chitosan sponges for local synergistic infection therapy: a pilot study.

Authors:  J Keaton Smith; Abteen R Moshref; Jessica A Jennings; Harry S Courtney; Warren O Haggard
Journal:  Clin Orthop Relat Res       Date:  2013-04-20       Impact factor: 4.176

4.  Development of a procedure for discriminating among Escherichia coli isolates from animal and human sources.

Authors:  Shukui Guan; Renlin Xu; Shu Chen; Joseph Odumeru; Carlton Gyles
Journal:  Appl Environ Microbiol       Date:  2002-06       Impact factor: 4.792

5.  Biological cost of rifampin resistance from the perspective of Staphylococcus aureus.

Authors:  Thomas A Wichelhaus; Boris Böddinghaus; Silke Besier; Volker Schäfer; Volker Brade; Albrecht Ludwig
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  Susceptibilities of Mycoplasma fermentans and Mycoplasma hyorhinis to membrane-active peptides and enrofloxacin in human tissue cell cultures.

Authors:  Ran Nir-Paz; Marie-Christine Prévost; Pierre Nicolas; Alain Blanchard; Henri Wróblewski
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  Genetic modification of potato against microbial diseases: in vitro and in planta activity of a dermaseptin B1 derivative, MsrA2.

Authors:  Milan Osusky; Lubica Osuska; William Kay; Santosh Misra
Journal:  Theor Appl Genet       Date:  2005-06-10       Impact factor: 5.699

8.  Co-occurrence of antibiotic and metal resistance genes revealed in complete genome collection.

Authors:  Li-Guan Li; Yu Xia; Tong Zhang
Journal:  ISME J       Date:  2016-12-13       Impact factor: 10.302

9.  Generic antibiotic industries: Challenges and implied strategies with regulatory perspectives.

Authors:  M Venkatesh; V G Bairavi; K C Sasikumar
Journal:  J Pharm Bioallied Sci       Date:  2011-01

10.  "One-size-fits-all"? Optimizing treatment duration for bacterial infections.

Authors:  Patricia Geli; Ramanan Laxminarayan; Michael Dunne; David L Smith
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.